Clinical trials
Phase 2 Recurrence trials in Russia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Terminated | 4 |
| Unknown status | 3 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 5 |
| Pfizer | 2 |
| St. Petersburg State Pavlov Medical University | 2 |
| Eli Lilly and Company | 1 |
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 1 |
| GlaxoSmithKline | 1 |
| Janssen-Cilag International NV | 1 |
| Merck Sharp & Dohme LLC | 1 |
| National Research Center for Hematology, Russia | 1 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 19 |
| Hodgkin Disease | 3 |
| Neoplasm Metastasis | 3 |
| Neoplasms | 3 |
| Multiple Myeloma | 2 |
| Multiple Sclerosis | 2 |
| Multiple Sclerosis, Relapsing-Remitting | 2 |
| Adenocarcinoma | 1 |
| Endometrial Neoplasms | 1 |
| Gastrointestinal Stromal Tumors | 1 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.